Genmab — Juni 2018
-
@StockBull - der er jo dog den dårlige nyhed om solide. Men ellers har du ret, så ser det ud til at hele lortet er styret af TA, hvilket er 100% grotesk. Jeg savner en diskussion af, om shorting burde være forbudt som det tidligere har været. Der er ingen tvivl om at det skaber enorm utryghed hos småinvestorer, og det mener jeg er dybt skadeligt for aktiekulturen.
-
Der er mange professionelle, der har travlt med at fremhæve en masse positive (set med deres øjne) egenskaber ved shorting. Men det er altså gift for privates lyst og motivation til at investere, når man udsættes for kæmpestore, milliardfonde, der bare tromler ind over det hele.
-
Genmab has also posted some of the posters from ASCO http://ir.genmab.com/downloads.cfm
-
and maybe someday ALL, who knows.. https://www.nature.com/articles/s41409-018-0222-5
-
Godt nok en tam omsætning i dag.
-
the Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors started recruiting. That is pretty fast, was put on end march. https://clinicaltrials.gov/ct2/history/NCT03485209?A=1&B=4&C=merged
-
Takeda also starts recruiting Ninlaro/Dara/Dex https://clinicaltrials.gov/ct2/history/NCT03439293?A=2&B=3&C=merged
-
also starts recruiting
https://clinicaltrials.gov/ct2/history/NCT03384654?A=6&B=7&C=merged
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind